| Literature DB >> 30797739 |
Ning Shao1, Yao Zhu2, Ding Wei Ye3.
Abstract
1. mCRPC patients with gDDRm exhibit a good response to first abiraterone/enzalutamide treatments, despite this was not statistically significant. 2. The different detections of gDDRm and treatments (abiraterone or enzalutamide), indeed, are influential factors.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30797739 DOI： 10.1016/j.euf.2019.02.011
Source DB: PubMed Journal: Eur Urol Focus ISSN： 2405-4569